What is PMVP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PMVP?

P/E (TTM) is n/a and 52-week range is $1.02 to $1.91 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PMVP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PMVP?

The company profile lists net income (TTM) near $-75M, EPS (TTM) near $-1.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PMV Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Princeton, New Jersey, US, 53.3M shares outstanding, ISIN US69353Y1038 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

PMV Pharmaceuticals Inc

$PMVP

Health Care · Biotechnology

IR Run Scenarios

$1.52

+2.01%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The firm is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.

Employees

Website

www.pmvpharma.com/

IPO

2020-09-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)